Systems and methods described provide dynamic and intelligent ways to change the required level of user interaction during use of a monitoring device. The systems and methods generally relate to real time switching between a first or initial mode of user interaction and a second or new mode of user interaction. In some cases, the switching will be automatic and transparent to the user, and in other cases user notification may occur. The mode switching generally affects the user’s interaction with the device, and not just internal processing. The mode switching may relate to calibration modes, data transmission modes, control modes, or the like.

A body fluid analyte detection device, includes: a transmitter, provided with at least one first clamping part; a bottom shell, provided with a second clamping part corresponding to the first clamping part, the transmitter being assembled on the bottom shell by mutual snap fitting of the first clamping part and the second clamping part, the bottom shell including a fixing part and a force application part, and the fixing part being fixed and applying a force to the force application part in a direction to disable the bottom shell, so that the first clamping part and the second clamping part are separated from each other, and then the bottom shell and the transmitter are separated; a battery, used for supplying power to the transmitter; a sensor, used for detecting body fluid analyte parameter information and electrically connected to the transmitter to transmit a parameter signal.

A body fluid analyte detection apparatus is provided. Applying a force to a force applying portion of a bottom case in one direction can make the bottom case fail, and then separate the bottom case and a transmitter from each other. Before the bottom case is mounted to a human body, the bottom case is fixed together with a mounting unit by means of a snap-fit portion. Operation steps of a user when separating the bottom case from the transmitter are reduced, and the failure rate of the bottom case before being mounted to the human body is also reduced, thereby improving the user experience, and enhancing the reliability of the body fluid analyte detection apparatus.

Embodiments relate to an insertion device that includes: a plunger coupled with a lock collar. The insertion device houses contents including: a striker including self-locking striker snap arm(s) where the striker is kept from firing by a striker spring captured between the plunger and the striker when the insertion device is in a cocked position; a sensor assembly; and a needle carrier that holds a piercing member, the needle carrier captured between the striker and a needle carrier spring where a self-releasing snap(s) keeps the needle carrier cocked, where the plunger prevents the self-releasing snap(s) from repositioning and releasing the needle carrier. The striker fires the needle carrier such that the self-locking striker snap arm(s) are positioned to allow the striker to snap down. The needle carrier is then retracted when the user releases the plunger and the piercing member is encapsulated within the insertion device.

The present disclosure relates to methods of collecting and testing bacteria containing samples from within the gastrointestinal (GI) tract of a subject. The methods may include disposing an ingestible device in the GI tract, collecting a bacteria-containing sample from the GI tract, selectively lysing eukaryotic cells in the sample by combining the sample with a dried reagent, exposing bacteria in the sample to resazurin in the ingestible device to produce resorufin, emitting light from the ingestible device, the emitted light being filtered through an optical filter to control for scatter so that the light interacts with the resorufin to produce fluorescence, and measuring a total fluorescence from the resorufin; or a rate of change of fluorescence from the resorufin as a function of time within the GI tract of the subject; and correlating the measured parameter to a number of viable bacterial cells in the sample.

A modified polyisobutylene-based polymer, method of making, and a medical device that includes such polymer, wherein the modified polyisobutylene-based polymer includes urethane, urea, or urethane-urea groups, hard segments, and soft segments, wherein the soft segments comprise phenoxy-containing polyisobutylene residues, and the hard segments include diisocyanate residues and optionally chain extender residues.

Embodiments described herein include a device and a non-transitory computer-readable medium. The device includes one or more processors, an analyte sensor, a communication module, and memories. The processors are configured to generate analyte data indicative of a monitored analyte level measured by the analyte sensor corresponding to a first time, generate analyte data indicative of the monitored analyte level measured by the analyte sensor corresponding to a second time, calculate a correction parameter based on the analyte data corresponding to the analyte data corresponding to the first time and analyte data corresponding to the second time, and perform a lag correction to obtain the monitored analyte level using at least the calculated correction parameter. The calculated correction parameter comprises a lag time determined from the analyte data. The performed lag correction comprises a linear correction model based on the calculated correction parameter.

Implementations relate generally to devices for measuring an analyte in a host. Implementations may provide reduced sizes for wearable devices including a transcutaneous analyte sensor for analyte measurement.

Systems and methods for providing sensitive and specific alarms indicative of glycemic condition are provided herein. In an embodiment, a method of processing sensor data by a continuous analyte sensor includes: evaluating sensor data using a first function to determine whether a real time glucose value meets a first threshold; evaluating sensor data using a second function to determine whether a predicted glucose value meets a second threshold; activating a hypoglycemic indicator if either the first threshold is met or if the second threshold is predicted to be met; and providing an output based on the activated hypoglycemic indicator.

A method of administering insulin includes receiving scheduled glucose time intervals and obtaining glucose data of a patient that includes glucose measurements, glucose times, and insulin dosages previously administered by the patient. The method also includes applying a set of filters to identify which of the glucose measurements associated with at least one of the scheduled time intervals are usable and which of the glucose measurements associated with the at least one scheduled time interval are unusable. The method also includes aggregating the glucose measurements associated with the at least one scheduled time interval identified as usable to determine a representative aggregate glucose measurement and determining a next recommended insulin dosage for the patient based on the representative aggregate glucose measurement and the insulin dosages previously administered by the patient.